[CNP_S2] Symposium2
Aims and scope for schizophrenia pharmacotherapy guidelines revised edition

[CNP-S2-8] The aim of the revision on the Japanese Guideline for Pharmacological Therapy of Schizophrenia, espacially the chapter on the side effects of antipsychotics

^○Takashi TSUBOI¹, Masakazu HATANO², Tsutomu NAGAI³, Tsuyoshi SASAKI⁴, Haruhiko ODA⁵, Satoru ESUMI⁶, Hiroki YAMADA⁷, Hiroshi KADOTANI⁸, Yasuhiko HASHIMOTO⁹, Tetsu TOMITA¹⁰ (1. Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan, 2. Department of Clinical Pharmacy, Fujita Health University School of Medicine, Aichi, Japan, 3. Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan, 4. Department of Child Psychiatry, Chiba-University Hospital, Chiba, Japan, 5. Hyogo Mental Health Center, Hyogo, Japan, 6. Department of Pharmacy, Okayama University Hospital, Okayama, Japan, 7. Department of Psychiatry, School of Medicine, Showa University, Tokyo, Japan, 8. Department of Sleep and Behavioral Sciences, Shiga University of Medical Science, Shiga, Japan, 9. Factly of clinical pharmacy, KobeGakuin university, Hyogo, Japan, 10. Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Aomori, Japan)